European Vaccine Initiative
20
3
8
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.0%
1 terminated/withdrawn out of 20 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
Role: collaborator
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
Role: collaborator
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
Role: collaborator
Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults
Role: collaborator
A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
Role: lead
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
Role: lead
Evaluation of Electronic Pregnancy Registers and Mobile Applications for Monitoring Pregnancy Outcomes ( EVAPREAP )
Role: lead
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Role: collaborator
Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine
Role: collaborator
InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
Role: collaborator
Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida
Role: collaborator
Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine
Role: collaborator
A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)
Role: collaborator
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Role: collaborator
Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib
Role: collaborator
Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted
Role: collaborator
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
Role: lead
Sporozoite Challenge of Polyprotein Vaccinees
Role: lead
GMZ2-Aluminum Hydroxide Phase I, Tübingen
Role: lead
Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP
Role: lead
All 20 trials loaded